We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Response to vaccination against SARS‐CoV‐2 in 168 patients with Waldenström macroglobulinaemia: A French Innovative Leukaemia Organization study.
- Authors
Tomowiak, Cécile; Leblond, Véronique; Laribi, Kamel; Baron, Marine; Puppinck, Christian; Gérard, Paulette; Courret, Elodie; Gorochov, Guy; Sterlin, Delphine; Tournilhac, Olivier; Morel, Pierre; Cymbalista, Florence; Roos‐Weil, Damien
- Abstract
Keywords: antibody response; COVID; SARS-CoV-2; vaccination; Waldenström EN antibody response COVID SARS-CoV-2 vaccination Waldenström 424 427 4 05/10/22 20220515 NES 220515 Patients with haematological malignancies have shown an increased risk of morbidity and mortality with regard to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.1,2 Immunocompromised patients have been excluded from initial trials evaluating SARS-CoV-2 mRNA vaccines3-5 and there is a crucial need to assess vaccine efficacy among these patients. Underlying disease and B-cell-directed therapies might adversely affect the production of antibodies in response to SARS-CoV-2 vaccination in Waldenström macroglobulinaemia (WM) patients. TN patients had the highest response rate (94.7%, I n i = 36/38) compared to previously treated patients (66.7%, I n i = 64/96; I p i = 0.003), most of whom received chemoimmunotherapy (CIT) (Table 1), and to patients on therapy (38.2%, I n i = 13/34; I p i < 0.001) (Figure 1A). Response rates were markedly different according to the time interval between last therapy and vaccination, as they were respectively 13.8% ( I n i = 4/29) and 89.6% (60/67) ( I p i < 0.001) for WM patients off therapy with a <1-year and >1-year time interval.
- Subjects
SARS-CoV-2
- Publication
British Journal of Haematology, 2022, Vol 197, Issue 4, p424
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.18055